Aripiprazole reverses paliperidone-induced hyperprolactinemia

Actas Esp Psiquiatr. 2012 Sep-Oct;40(5):290-2. Epub 2012 Sep 1.

Abstract

Hyperprolactinemia is a common side effect of antipsychotic treatments. Existing alternatives to resolve this problem include decreasing the antipsychotic dose or switching to a different antipsychotic agent. Nevertheless, said modifications can sometimes lead to decompensation of the patient. We report a clinical case of a female patient in whom the combined treatment of 5 mg/day of aripiprazole (5 mg/day) reversed paliperidoneinduced hyperprolactinemia within four weeks.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Aripiprazole
  • Female
  • Humans
  • Hyperprolactinemia / chemically induced*
  • Hyperprolactinemia / drug therapy*
  • Isoxazoles / adverse effects*
  • Paliperidone Palmitate
  • Piperazines / therapeutic use*
  • Pyrimidines / adverse effects*
  • Quinolones / therapeutic use*

Substances

  • Antipsychotic Agents
  • Isoxazoles
  • Piperazines
  • Pyrimidines
  • Quinolones
  • Aripiprazole
  • Paliperidone Palmitate